Literature DB >> 8806556

Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma.

B Wang1, Y C Ge, P Palasanthiran, S H Xiang, J Ziegler, D E Dwyer, C Randle, D Dowton, A Cunningham, N K Saksena.   

Abstract

Earlier studies on HIV-1 strains from HIV-1-infected long-term nonprogressors (LTNP) have reported that nef deletions and/or attenuations may be crucial in the survival of these patients. Other reports have suggested that the nef gene may not be the only gene involved, but attenuations in other accessory genes (vif, vpr, vpu), which play an important role in the viral life cycle, may be similarly important in chronic HIV-1 infection in LTNPs. Here we show the molecular and phylogenetic analyses of the vpr gene in HIV-1 strains derived from both blood and plasma of an HIV-1 infected long-surviving mother-child pair which has survived for > 13 years with HIV infection: both have maintained stable CD4+ T-cell counts. Analyses of blood-and plasma-derived HIV-1 vpr clones indicated the presence of defects (insertions and deletions) and length polymorphisms. Interestingly, all the vpr defects in PBMCs and plasma were clustered at the C-terminus of the Vpr protein, between amino acid residues 83 and 89, which has been implicated in the G2 cell cycle arrest as a step to early HIV-1 infection. In contrast, the vpr sequence analysis of HIV-1 strains derived from 30 different patients, who either died of AIDS-related illnesses or have AIDS, showed neither C-terminal defects nor length polymorphism in the vpr gene. Also, secondary structure predictions suggest that the naturally occurring mutations at the C-terminal region (aa 83-89) have the potential to affect the secondary structure of the Vpr protein. Also, in some cases, the out-of-frame mutations and the length polymorphisms affect the tat gene reading frame. Together, these mutations may have potential significance in conferring chronic HIV-1 infection in this long-surviving nonprogressing mother-child pair.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806556     DOI: 10.1006/viro.1996.0471

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  39 in total

1.  Evidence for a cytopathogenicity determinant in HIV-1 Vpr.

Authors:  Mohan Somasundaran; Mark Sharkey; Beda Brichacek; Katherine Luzuriaga; Michael Emerman; John L Sullivan; Mario Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

2.  Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis.

Authors:  Julian J Lum; Oren J Cohen; Zilin Nie; Joel G Weaver; Timothy S Gomez; Xiao-Jian Yao; David Lynch; André A Pilon; Nanci Hawley; John E Kim; Zhaoxia Chen; Michael Montpetit; Jaime Sanchez-Dardon; Eric A Cohen; Andrew D Badley
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

3.  A human immunodeficiency virus type 1-infected individual with low viral load harbors a virus variant that exhibits an in vitro RNA dimerization defect.

Authors:  Hendrik Huthoff; Atze T Das; Monique Vink; Bep Klaver; Fokla Zorgdrager; Marion Cornelissen; Ben Berkhout
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest.

Authors:  Tomoshige Kino; Alexander Gragerov; Antonio Valentin; Maria Tsopanomihalou; Galina Ilyina-Gragerova; Rebecca Erwin-Cohen; George P Chrousos; George N Pavlakis
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape.

Authors:  Biswanath Majumder; Michelle L Janket; Elizabeth A Schafer; Keri Schaubert; Xiao-Li Huang; June Kan-Mitchell; Charles R Rinaldo; Velpandi Ayyavoo
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy.

Authors:  Celia Chui; Peter K Cheung; Chanson J Brumme; Theresa Mo; Zabrina L Brumme; Julio S G Montaner; Andrew D Badley; P Richard Harrigan
Journal:  AIDS Res Hum Retroviruses       Date:  2006-07       Impact factor: 2.205

7.  SIV Vpr evolution is inversely related to disease progression in a morphine-dependent rhesus macaque model of AIDS.

Authors:  Richard J Noel; Anil Kumar
Journal:  Virology       Date:  2006-10-24       Impact factor: 3.616

8.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators.

Authors:  Tomoshige Kino; Alexander Gragerov; Olga Slobodskaya; Maria Tsopanomichalou; George P Chrousos; George N Pavlakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.